Merck & Co., Inc. (MRK)
| Market Cap | 239.29B |
| Revenue (ttm) | 64.17B |
| Net Income (ttm) | 17.12B |
| Shares Out | 2.53B |
| EPS (ttm) | 6.74 |
| PE Ratio | 14.05 |
| Forward PE | 10.54 |
| Dividend | $3.24 (3.42%) |
| Ex-Dividend Date | Mar 17, 2025 |
| Volume | 20,305,156 |
| Open | 94.98 |
| Previous Close | 95.23 |
| Day's Range | 93.60 - 95.38 |
| 52-Week Range | 81.04 - 134.63 |
| Beta | 0.36 |
| Analysts | Buy |
| Price Target | 120.31 (+27.0%) |
| Earnings Date | Apr 24, 2025 |
About MRK
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The company offers human health pharmaceutical for various areas, including oncology, vaccines, hospital acute care, cardiovascular, virology, neuroscience, and diabetes under the Keytruda, Welireg, Gardasil, ProQuad, M−M−R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janu... [Read more]
Financial Performance
In 2024, Merck & Co.'s revenue was $64.17 billion, an increase of 6.74% compared to the previous year's $60.12 billion. Earnings were $17.12 billion, an increase of 4589.59%.
Financial StatementsAnalyst Forecast
According to 17 analysts, the average rating for MRK stock is "Buy." The 12-month stock price forecast is $120.31, which is an increase of 27.00% from the latest price.
News
Merck prevails in Gardasil safety litigation
A federal judge has ruled in favor of Merck in litigation accusing the drugmaker of concealing the risks of Gardasin, a vaccine to prevent cervical and other fatal cancers.
Merck opens vaccine manufacturing facility in North Carolina
Merck said on Tuesday it has opened a new $1 billion, 225,000-square-foot facility dedicated to vaccine manufacturing at its Durham, North Carolina, site.
Merck Unveils New Facility to Increase Vaccine Production Capacity
DURHAM, N.C.--(BUSINESS WIRE)--Merck Unveils New Facility to Increase Vaccine Production Capacity.
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Merck & Co.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Merck To Contact Him Directly To Discuss Their Options
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Merck & Co.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Merck To Contact Him Directly To Discuss Their Options If you purchased or acquired s...
New version of Merck's cancer drug faces patent battle, WSJ reports
Merck has asked the U.S. patent office to reconsider patents that could prevent it from selling a new version of its cancer drug Keytruda, the Wall Street Journal reported on Wednesday.
Dogs Of The Dow Chase A "Safer" Buy For March
Verizon is the only Dow Dog meeting the ideal of dividends from $1K invested exceeding its single share price, making it a 'safer' buy. Analysts project net gains of 13.06% to 37.60% from the top ten ...
Trends Shaping the Global Livestock Monitoring Market 2025-2031, Featuring Case Study Analysis and Profiles of Industry Giants - Merck & Co., GEA Group, DeLaval, Nedap, Afimilk & More
Increasing Use of Smart Wearables for Livestock and Integration of Blockchain Technology Presents Lucrative Opportunities for the $2.57 Billion Market Increasing Use of Smart Wearables for Livestock a...
Merck & Co., Inc. (MRK) Presents at TD Cowen 45th Annual Health Care Conference (Transcript)
Start Time: 14:30 January 1, 0000 3:05 PM ET Merck & Co., Inc.
Investors in Merck & Co., Inc. Should Contact The Gross Law Firm Before April 14, 2025 to Discuss Your Rights – MRK
NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Merck & Co., Inc. (NYSE: MRK).
Buy These Mispriced Dividend Icons For Retirement Income
Realty Income and Merck offer compelling value with strong fundamentals, attractive valuations, and reliable, growing income streams, making them opportunistic buys for long-term investors. Realty Inc...
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 14, 2025 in Merck Lawsuit - MRK
NEW YORK , March 3, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Merck & Co., Inc. (NYSE: MRK). Shareholders who purchased shares of MRK during the class peri...
My Top 10 High-Yield Dividend Stocks For March 2025
SPY stumbles in February, erasing some of its year-to-date gains. VYM is running strong and extends its lead over SPY in 2025. The top 10 stocks on the watchlist for March 2025 offer a 3.56% dividend ...
5 Relatively Secure And Cheap Dividend Stocks, Yields Upto 8% (March 2025)
This article is part of our monthly series where we highlight five large-cap, relatively safe, dividend-paying companies offering significant discounts to their historical norms. We go over our filter...
Deadline Approaching: Merck & Co (MRK) Investors Who Lost Money Urged To Contact Law Offices of Howard G. Smith
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith reminds investors of the upcoming April 14, 2025 deadline to file a lead plaintiff motion in the case filed on behalf of investors who pu...
Merck's Oncology Strength: Beating Wall Street Again
On February 4, Merck released financial results for Q4 2024, which, as in previous quarters, once again beat analysts' expectations. This was driven by a strong performance by its oncology franchise, ...
US drugmaker Merck to boost workforce in India, executive says
Drugmaker Merck , known as MSD outside of the U.S. and Canada, expects to increase its workforce across its India sites by the end of the year, a senior company executive said on Wednesday.
Merck expects cancer therapy Keytruda to be part of government price setting in 2026
Drugmaker Merck said on Tuesday it expects its top selling cancer therapy Keytruda to be selected in 2026 for government price setting, which would become effective on January 1, 2028.
10 Undervalued Dividend Growth Stocks: February 2025
I rank a selection of undervalued dividend growth stocks in Dividend Radar and present the ten top-ranked stocks for consideration. I use two valuation screens, one based on my fair value estimate, an...
FDA Grants Priority Review to Merck's Application for KEYTRUDA® (pembrolizumab) Plus Standard of Care as Perioperative Treatment for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has accepted for prior...
Don't Get Left Behind - The Great Rotation Into Dividend Stocks Is Here
Despite significant market events, industrial and tech stocks have had similar returns since 2020, indicating a potential long-term rotation favoring value stocks. Higher inflation and interest rates ...
Merck to Participate in the TD Cowen 45th Annual Health Care Conference
RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Participate in the TD Cowen 45th Annual Health Care Conference.
Securities Fraud Investigation Into Merck & Co (MRK) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Merck & Co (“Merck” or th...
I'm Buying Discounted Dividend Icons Up To 6% Yield
Great dividend stocks should offer a mix of durability, solid income generation, and growth prospects. In this article, I highlight 2 such names, both of which are trading at discounted valuations com...
Merck & Co (MRK) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Merck & Co (“Merck” or the “Company”) (NYSE: MRK) investors concerning the Company's possible vio...